| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
1 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; 2 Department of Epidemiology, Harvard School of Public Health; 3 Reproductive Endocrinology Unit Laboratory, Massachusetts General Hospital, Boston, Massachusetts
Requests for reprints: Shelley S. Tworoger, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 3rd Floor, 181 Longwood Avenue, Boston, MA 02115. Phone: 617-525-2087; Fax: 617-525-2008; E-mail: nhsst{at}channing.harvard.edu.
Recent evidence suggests that prolactin may be positively associated with postmenopausal breast cancer risk; however, little data are available in younger women. Therefore, we conducted a prospective, nested case-control study to examine the relationship between plasma prolactin concentrations and breast cancer risk in predominately premenopausal women from the Nurses' Health Study II. Blood samples were collected from 1996 to 1999. The analysis includes 316 cases of breast cancer diagnosed after blood donation and before June 1, 2003, who had two controls matched on age, fasting status, time of day and month of blood collection, race/ethnicity, and timing of blood draw within the menstrual cycle. Sixty-three percent of participants provided a timed follicular and luteal menstrual phase blood sample; other women provided a single untimed sample. When including all women, we observed a positive association between prolactin and breast cancer risk [relative risk (RR), top quartile versus bottom quartile, 1.5; 95% confidence interval (95% CI), 1.0-2.3; Ptrend = 0.03] that was slightly stronger among estrogen receptor–positive/progesterone receptor–positive tumors (comparable RR, 1.9; 95% CI, 1.1-3.3; Ptrend = 0.04). Associations were similar among premenopausal women only. However, we did not find an association between prolactin and breast cancer risk among the subset of women who only provided timed samples (comparable RR, average of timed samples, 1.3; 95% CI, 0.8-2.3; Ptrend = 0.40). The association seemed stronger among women 
45 years old and for cases diagnosed within 
4 years of blood collection. Our data suggest a modest positive association between prolactin and breast cancer risk among predominately premenopausal women; however, further follow-up is needed to increase power for subgroup analyses. (Cancer Res 2006; 66(4): 2476-82)
This article has been cited by other articles:
|
|
 |
|
  S. M Dursun, H. J. Wildgust, P. Strickland, G. M Goodwin, L. Citrome, and M. Lean The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness J Psychopharmacol, March 1, 2008; 22(2_suppl): 3 - 5. [PDF]
|
|
|
|
|
|
P. W. Harvey, D. J. Everett, and C. J. Springall Adverse effects of prolactin in rodents and humans: breast and prostate cancer J Psychopharmacol, March 1, 2008; 22(2_suppl): 20 - 27. [Abstract] [PDF]
|
|
|
|
|
|
C. Bushe, M. Shaw, and R. C Peveler A review of the association between antipsychotic use and hyperprolactinaemia J Psychopharmacol, March 1, 2008; 22(2_suppl): 46 - 55. [Abstract] [PDF]
|
|
|
|
|
|
C. Bushe, D. Yeomans, T. Floyd, and S. M Smith Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics J Psychopharmacol, March 1, 2008; 22(2_suppl): 56 - 62. [Abstract] [PDF]
|
|
|
|
|
|
R. C Peveler, D. Branford, L. Citrome, P. Fitzgerald, P. W Harvey, R. I. Holt, L. Howard, D. Kohen, I. Jones, V. O'Keane, et al. Antipsychotics and hyperprolactinaemia: Clinical recommendations J Psychopharmacol, March 1, 2008; 22(2_suppl): 98 - 103. [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, I-M. Lee, J. E. Buring, and S. E. Hankinson Plasma Androgen Concentrations and Risk of Incident Ovarian Cancer Am. J. Epidemiol., January 15, 2008; 167(2): 211 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S Schernhammer, S. S Tworoger, A H. Eliassen, S. A Missmer, J. M Holly, M. N Pollak, and S. E Hankinson Body shape throughout life and correlations with IGFs and GH Endocr. Relat. Cancer, September 1, 2007; 14(3): 721 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, I-M. Lee, J. E. Buring, M. N. Pollak, and S. E. Hankinson Insulin-like Growth Factors and Ovarian Cancer Risk: A Nested Case-Control Study in Three Cohorts Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1691 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, B. Sorensen, J. Chubak, M. Irwin, F. Z. Stanczyk, C. M. Ulrich, J. Potter, and A. McTiernan Effect of a 12-Month Randomized Clinical Trial of Exercise on Serum Prolactin Concentrations in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 895 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, A. H. Eliassen, P. Sluss, and S. E. Hankinson A Prospective Study of Plasma Prolactin Concentrations and Risk of Premenopausal and Postmenopausal Breast Cancer J. Clin. Oncol., April 20, 2007; 25(12): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, I-M. Lee, J. E. Buring, B. Rosner, B. W. Hollis, and S. E. Hankinson Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Incident Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 783 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, A. H. Eliassen, T. Kelesidis, G. A. Colditz, W. C. Willett, C. S. Mantzoros, and S. E. Hankinson Plasma Adiponectin Concentrations and Risk of Incident Breast Cancer J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hemminki, A. Forsti, and J. Ji Incidence and familial risks in pituitary adenoma and associated tumors Endocr. Relat. Cancer, March 1, 2007; 14(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Eliassen, S. S. Tworoger, C. S. Mantzoros, M. N. Pollak, and S. E. Hankinson Circulating Insulin and C-Peptide Levels and Risk of Breast Cancer among Predominately Premenopausal Women Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 161 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, A. H. Eliassen, S. A. Missmer, H. Baer, J. Rich-Edwards, K. B. Michels, R. L. Barbieri, M. Dowsett, and S. E. Hankinson Birthweight and Body Size throughout Life in Relation to Sex Hormones and Prolactin Concentrations in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2494 - 2501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Eliassen, S. A. Missmer, S. S. Tworoger, D. Spiegelman, R. L. Barbieri, M. Dowsett, and S. E. Hankinson Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst, October 4, 2006; 98(19): 1406 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Faupel-Badger, S. A. Prindiville, D. Venzon, B. K. Vonderhaar, J. A. Zujewski, and J. Eng-Wong Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1153 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, S. A. Missmer, A. H. Eliassen, D. Spiegelman, E. Folkerd, M. Dowsett, R. L. Barbieri, and S. E. Hankinson The Association of Plasma DHEA and DHEA Sulfate with Breast Cancer Risk in Predominantly Premenopausal Women. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
